Business
Lucid Diagnostics Reports Publication of Future Effective Foundational Local Coverage Determination by Medicare Administrative Contractor Noridian Healthcare Solutions
Lucid's CLIA laboratory, which performs its EsoGuard test, operates within Noridian's jurisdiction Noridian's foundational LCD, to become effective May 28,
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"Lucid's CLIA laboratory, which performs its EsoGuard test, operates within Noridian's jurisdiction\n Noridian's foundational LCD, to become effective May 28, 2023, closely aligns with the LCD recently published by the MolDx Program\nLucid remains focused on securing clinical utility data and submitting EsoGuard for Technical Assessment and coverage under these foundational LCDs later this year\nNEW YORK, April 18, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid Diagnostics\" or \"Lucid\"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), announced that Noridian Healthcare Solutions (\"Noridian\"), the Medicare Administrative Contractor (\"MAC\") whose geographic Jurisdiction E covers Lucid's CLIA laboratory in Lake Forest, CA, has published a Future Effective Local Coverage Determination (\"LCD\") DL39262, on molecular testing for esophageal precancer and cancer in Medicare beneficiaries, to become effective May 28, 2023.\n\n \n \n \n \n \n \n\n \nAs with the foundational LCD issued last month by the Palmetto GBA MAC's MolDX Program (\"MolDX\"), the Noridian foundational LCD, entitled \"Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia\" provides the criteria for future coverage of individual tests within this category, such as Lucid's EsoGuard® Esophageal DNA Test (\"EsoGuard\"), following submission of each test for Technical Assessment. EsoGuard is the only commercially available test in this category and the first such test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk patients. This foundational LCD closely aligns with the MolDx LCD and incorporates substantially all the constructive feedback provided during comment periods last year.\n\"The publication of this foundational LCD is a very important milestone as we seek to expand EsoGuard testing access to Medicare beneficiaries,\" said Lishan Aklog, M.D., Lucid's Chairman & Chief Executive Officer. \"As the MAC covering our laboratory, Noridian will be processing all Medicare claims for EsoGuard across the country. We look forward to completing and publishing data from our ongoing clinical utility studies and submitting EsoGuard for Tech...